Affiliation:
1. Department of Surgery, Toho University Sakura Medical Center, Chiba 285-8741, Japan
2. Frontier Surgery, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan
Abstract
Background: Recently, neoadjuvant therapy and the succeeding surgery for advanced esophageal cancer have been evaluated. In particular, the response to the therapy has been found to affect surgical outcomes, and thus a precise evaluation of treatment effect is important for this strategy. In this study, articles on qualitative diagnostic modalities to evaluate tumor activities were reviewed, and the diagnostic indices were examined. Methods: For prediction of the effect, perfusion CT and diffusion MRI were estimated. For the histological response evaluation, perfusion CT, diffusion-MRI, and FDG-PET were estimated. For downstaging evaluation of T4, tissue-selective image reconstruction using enhanced CT was estimated and diagnostic indices were reviewed. Results: The prediction of the effect using perfusion CT with ‘pre CRT blood flow’ and diffusion MRI with ‘pre CRT ADC value’; the estimation of the histological response using perfusion CT with ‘post CRT blood flow reduction, using diffusion MRI with ‘post CRT ADC increasing’, and using FDG-PET with ‘post CRT SUV reduction’; and the downstaging evaluation of T4 using CT image reconstruction with ‘fibrous changed layer’ were performed well, respectively. Conclusions: Qualitative imaging modalities for prediction or response evaluation of neoadjuvant therapy for progressive esophageal cancer were useful for the decision making of the treatment strategy of the multidisciplinary treatment.
Reference53 articles.
1. Neoadjuvant strategies in resectable carcinoma esophagus: A meta-analysis of randomized trials;Kumar;World J. Surg. Oncol.,2020
2. Neoadjuvant Chemoradiotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Squamous Cell Carcinoma of the Esophagus (NEOCRTEC5010): A Phase III Multicenter, Randomized, Open-Label Clinical Trial;Yang;Clin. Oncol.,2018
3. Phase III study of tri-modality combination therapy with induction docetaxel plus cisplatin and 5-fluorouracil versus definitive chemoradiotherapy for locally advanced unresectable squamous-cell carcinoma of the thoracic esophagus (JCOG1510, TRIANgLE);Terada;Jpn. J. Clin. Oncol.,2019
4. Clinical Implications of Conversion Surgery After Induction Therapy for T4b Thoracic Esophageal Squamous Cell Carcinoma;Miyata;Ann. Surg. Oncol.,2019
5. Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus or gastroesophageal junction: Long-term results of a randomized clinical trial;Klevebro;Dis. Esophagus,2018